AGPS and diffuse large B-cell lymphoma: While some R/R DLBCL patients may have previously been administered rituximab and could potentially have developed anti-rituximab antibodies that may theoretically cross-react with the antibody component of polatuzumab vedotin, clinical studies have shown that baseline levels of ADAs to polatuzumab vedotin is low (see below).